Publication | Closed Access

Prostate high dose-rate brachytherapy as monotherapy for low and intermediate risk prostate cancer: Early toxicity and quality-of life results from a randomized phase II clinical trial of one fraction of 19Gy or two fractions of 13.5Gy

Radiation TherapyMedicineBrachytherapyQuality-of Life ResultsProstatic DiseaseOncologyRadiation OncologyEarly Toxicity